GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allied Biotech Corp (ROCO:1780) » Definitions » EBIT

Allied Biotech (ROCO:1780) EBIT : NT$135.3 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Allied Biotech EBIT?

Allied Biotech's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was NT$52.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$135.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Allied Biotech's annualized ROC % for the quarter that ended in Dec. 2023 was 4.48%. Allied Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 8.92%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Allied Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 7.67%.


Allied Biotech EBIT Historical Data

The historical data trend for Allied Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allied Biotech EBIT Chart

Allied Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 142.50 110.52 28.83 196.79 135.34

Allied Biotech Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.79 86.23 110.56 83.37 51.98

Competitive Comparison of Allied Biotech's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Allied Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allied Biotech's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allied Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Allied Biotech's EV-to-EBIT falls into.



Allied Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$135.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allied Biotech  (ROCO:1780) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Allied Biotech's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=75.602 * ( 1 - 18.36% )/( (1403.382 + 1353.897)/ 2 )
=61.7214728/1378.6395
=4.48 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2215.515 - 224.136 - ( 847.447 - max(0, 993.546 - 1581.543+847.447))
=1403.382

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2078.904 - 96.822 - ( 724.772 - max(0, 828.687 - 1456.872+724.772))
=1353.897

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Allied Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=103.952/( ( (609.273 + max(501.642, 0)) + (593.995 + max(624.639, 0)) )/ 2 )
=103.952/( ( 1110.915 + 1218.634 )/ 2 )
=103.952/1164.7745
=8.92 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(109.208 + 605.771 + 16.169) - (224.136 + 0 + 5.3700000000001)
=501.642

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(108.623 + 601.475 + 18.645) - (96.822 + 0 + 7.282)
=624.639

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Allied Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=135.341/1764.912
=7.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allied Biotech EBIT Related Terms

Thank you for viewing the detailed overview of Allied Biotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Allied Biotech (ROCO:1780) Business Description

Traded in Other Exchanges
N/A
Address
No. 76 Tun Hua S. Road, Sec. 2, 12th Floor, Taipei, TWN
Allied Biotech Corp is a Taiwan based manufacturer of carotenoids. It manufactures carotenoid formulations for the food, supplement and feed industries. The company markets its products under the name Altratene.

Allied Biotech (ROCO:1780) Headlines

No Headlines